ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Akero Initiates Phase 2b HARMONY Study of Efruxifermin for NASH
March 01, 2021Akero Therapeutics has screened the first patients for its Phase 2b HARMONY study evaluating efruxifermin (EFX), the company's lead product candidate for the treatment of NASH. -
Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH
October 21, 2020Akero Therapeutics, Inc. announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to efruxifermin (EFX), an investigational FGF21 analog for the treatment of NASH.
Pharma Sources Insight January 2025
